Urinary system tumors - Renal cancer
Conditions
Interventions
Experimental Group (Double-strand ligation clip group):The operation was performed by the same medical team (with surgeons having over 5 years of experience in laparoscopic/robotic radical nephrectomy
Control group (non-consecutive ligation clip group):Surgery using non-continuous ligation clips.
Sponsors
The First People's Hospital of Yunnan Province
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Disease Diagnosis: Confirmed as renal cancer through pathological biopsy or imaging examination, and the clinical stage meets the surgical indications for the kidney. Surgical Procedure: Planned to undergo laparoscopic or robot-assisted laparoscopic radical nephrectomy, and the plan is to use ligating clips to handle the renal pedicle vessels, lymphatic vessels, and ureters and other structures. Patient Characteristics: Age not limited, gender not limited. Surgical Risks: American Society of Anesthesiologists (ASA) classification ?-?, no severe cardiopulmonary dysfunction, no coagulation disorders, no surgical contraindications. Informed Consent: The patient and their family signed the informed consent form, agreeing to participate in postoperative follow-up (at least 6 months), and being able to cooperate with imaging reexaminations (CT/MRI at 1, 3, and 6 months after surgery) and laboratory tests (blood routine, liver and kidney function).
Exclusion criteria
Exclusion criteria: Surgical contraindications: Previous history of major abdominal surgery resulting in severe abdominal adhesions, or severe variations in renal hilum vessels (such as multiple renal arteries with diameters > 10mm and complex course); planned to combine other organ resections (such as adrenal gland, spleen). Patient-related factors: Severe coagulation dysfunction (such as hemophilia, long-term use of anticoagulants and inability to discontinue them), or systemic infection (body temperature > 38.5?, white blood cell count > 15×10?/L); allergy to ligature clip materials (such as titanium alloy, polyethylene acid polymer allergy history); distant metastasis (such as lung, bone metastasis) or severe underlying diseases (such as end-stage kidney disease, decompensated liver cirrhosis), with expected survival < 1 year. Study interference factors: During the operation, other hemostasis instruments (such as vascular suturing devices) need to be combined to handle major blood vessels. Informed consent: The patient refused to use ligature clips or withdrew from the study halfway, unable to complete the full follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of the operation;The amount of bleeding during surgery;Complications 30 days after the operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Renal pedicle vascular treatment time;Postoperative hospital stay days;Efficiency of lymph node dissection;Cost-benefit ratio; | — |
Countries
China
Contacts
Public ContactJunfeng Yang
The First People's Hospital of Yunnan Province
Outcome results
None listed